Dr. Konstantinopoulos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Dana Farber Cancer Institute YC1424
Boston, MA 02215Phone+1 617-632-6232- Is this information wrong?
Education & Training
Harvard - MIT Health Sciences and TechnologyMMSc, Clinical Investigation, 2008 - 2010
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
SUNY Upstate Medical UniversityResidency, Internal Medicine, 2002 - 2005- University of Patras School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2022 - Present
NH State Medical License 2023 - 2025
MA State Medical License 2005 - 2025
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Start of enrollment: 2009 Mar 01
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
- A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.Xiong, N., Sawyer, H., Polak, M., Needham, H., Geddes, M., Koppermann, L., Shea, M., Castro, C., Cheng, S., Konstantinopoulos, P., Krasner, C., Liu, J., Matulonis, U.,...> ;Gynecologic Oncology Reports. 2024 Apr 1
- Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelicinactivation.Mariko Peterson, David L Kolin, Panagiotis A Konstantinopoulos> ;Frontiers in Oncology. 2024 Jan 1
- Transforming ovarian cancer care by targeting minimal residual disease.Amir A Jazaeri, Rachel Grisham, Anne Knisely, Stefani Spranger, Dmitriy Zamarin, R Tyler Hillman, Barrett C Lawson, Kathleen H Burns, Sanghoon Lee, Shannon N Westin, E...> ;Med. 2023 Nov 10
- Join now to see all
Lectures
- Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutate...2019 ASCO Annual Meeting - 6/1/2019
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- DYNLL1 Binds to MRE11 to Limit DNA End Resection in BRCA1-Deficient CellsPanagiotis Konstantinopoulos, MD, Nature
https://www.doximity.com/articles/804b7938-38f7-46ed-bc4f-f3b8235a8ea6
UpToDate, Wolters Kluwer Health - 2012-12-13
Press Mentions
New Class of Cancer Drug Halts Tumor Growth in Early Human TrialsJune 23rd, 2020
New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
Avelumab Active in Mismatch Repair-Deficient Endometrial CancerOctober 3rd, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
